Integrin subunit beta 2 antisense RNA 1 (ITGB2-AS1)

ITGB2-AS1, or integrin subunit beta 2 antisense RNA 1, is a long non-coding RNA (~21q22.3) upregulated in certain disease states, including rheumatoid arthritis and several cancers[1][2][4]. It acts primarily by regulating the expression of the integrin beta 2 (ITGB2) gene, likely through epigenetic and post-transcriptional mechanisms, thereby influencing immune cell migration, adhesion, and inflammation[1][4]. Mechanistically, higher ITGB2-AS1 expression increases ITGB2 mRNA and protein, contributing to enhanced cell migration and invasion—particularly notable in oncology settings such as breast cancer[2]. ITGB2-AS1 can serve as a diagnostic biomarker, notably for rheumatoid arthritis (RA), correlating with disease activity and autoimmune pathology, as well as a potential prognostic factor in certain tumors. There are currently no drugs targeting ITGB2-AS1 directly in the clinic, but its pivotal role in disease makes it a research focus for diagnostic and future therapeutic strategies[1][2][4].

Other names

ITGB2 antisense RNA 1 (non-protein coding)Integrin subunit beta 2 antisense RNA 1ITGB2-AS1

As a non-coding RNA, the therapeutic mechanisms would involve gene expression modulation (e.g., RNAi-mediated downregulation) rather than receptor/ligand binding or enzyme inhibition.